Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0036690 (
sepsis
)
59,461
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Microvascular barrier dysfunction is implicated in the initiation and progression of inflammation, posttraumatic complications,
sepsis
, ischaemia-reperfusion injury, atherosclerosis, and diabetes. Under physiological conditions, a precise equilibrium between endothelial cell-cell adhesion and actin-myosin-based centripetal tension tightly controls the semi-permeability of microvascular barriers.
Myosin light chain kinase
(
MLCK
) plays an important role in maintaining the equilibrium by phosphorylating myosin light chain (MLC), thereby inducing actomyosin contractility and weakening endothelial cell-cell adhesion.
MLCK
is activated by numerous physiological factors and inflammatory or angiogenic mediators, causing vascular hyperpermeability. In this review, we discuss experimental evidence supporting the crucial role of
MLCK
in the hyperpermeability response to key cell signalling events during inflammation. At the cellular level, in vitro studies of cultured endothelial monolayers treated with
MLCK
inhibitors or transfected with specific inhibiting peptides have demonstrated that induction of endothelial
MLCK
activity is necessary for hyperpermeability. Ex vivo studies of live microvessels, enabled by development of the isolated, perfused venule method, support the importance of
MLCK
in endothelial permeability regulation in an environment that more closely resembles in vivo tissues. Finally, the role of
MLCK
in vascular hyperpermeability has been confirmed with in vivo studies of animal disease models and the use of transgenic MLCK210 knockout mice. These approaches provide a more complete view of the role of
MLCK
in vascular barrier dysfunction.
...
PMID:Myosin light chain kinase in microvascular endothelial barrier function. 2047 30
Sepsis
-induced intestinal hyperpermeability is mediated by disruption of the epithelial tight junction, which is closely associated with the peri-junctional actin-myosin ring.
Myosin light chain kinase
(
MLCK
) phosphorylates the myosin regulatory light chain, resulting in increased permeability. The purpose of this study was to determine whether genetic deletion of
MLCK
would alter gut barrier function and survival from
sepsis
.
MLCK
-/-
and wild type (WT) mice were subjected to cecal ligation and puncture and assayed for both survival and mechanistic studies. Survival was significantly increased in
MLCK
-/-
mice (95% vs. 24%, p<0.0001). Intestinal permeability increased in septic WT mice compared to unmanipulated mice. In contrast, permeability in septic
MLCK
-/-
mice was similar to that seen in unmanipulated animals. Improved gut barrier function in
MLCK
-/-
mice was associated with increases in the tight junction mediators ZO-1 and claudin 15 without alterations in claudin 1, 2, 3, 4, 5, 7, 8, 13, occludin or JAM-A. Other components of intestinal integrity (apoptosis, proliferation and villus length) were unaffected by
MLCK
deletion as were local peritoneal inflammation and distant lung injury. Systemic IL-10 was decreased greater than 10-fold in
MLCK
-/-
mice; however, survival was similar between septic
MLCK
-/-
mice given exogenous IL-10 or vehicle. These data demonstrate that deletion of
MLCK
improves survival following
sepsis
, associated with normalization of intestinal permeability and selected tight junction proteins.
...
PMID:Myosin light chain kinase knockout improves gut barrier function and confers a survival advantage in polymicrobial sepsis. 2859 88